4.6 Article

Results of genetic analysis of 11 341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States

期刊

JOURNAL OF THROMBOSIS AND HAEMOSTASIS
卷 20, 期 9, 页码 2022-2034

出版社

WILEY
DOI: 10.1111/jth.15805

关键词

genetics; genomic structural variation; hemophilia A; hemophilia B; race factors

资金

  1. Biogen/Bioverativ
  2. Bioverativ, a Sanofi company
  3. Bayer
  4. BioMarin
  5. CSL Behring
  6. Genentech
  7. Grifols
  8. Hema Biologics
  9. LFB
  10. Novo Nordisk
  11. Octapharma
  12. Pfizer
  13. Sanofi
  14. Spark
  15. Takeda
  16. uniQure

向作者/读者索取更多资源

The findings of this study report the results of the largest hemophilia genotyping project performed to date. The results support the importance of comprehensive genetic approaches in hemophilia and contribute to a better understanding of variation in the F8 and F9 genes and the risks of inhibitor formation.
Background Hemophilia A (HA) and hemophilia B (HB) are rare inherited bleeding disorders. Although causative genetic variants are clinically relevant, in 2012 only 20% of US patients had been genotyped. Objectives My Life, Our Future (MLOF) was a multisector cross-sectional US initiative to improve our understanding of hemophilia through widespread genotyping. Methods Subjects and potential genetic carriers were enrolled at US hemophilia treatment centers (HTCs). Bloodworks performed genotyping and returned results to providers. Clinical data were abstracted from the American Thrombosis and Hemostasis Network dataset. Community education was provided by the National Hemophilia Foundation. Results From 2013 to 2017, 107 HTCs enrolled 11 341 subjects (68.8% male, 31.2% female) for testing for HA (n = 8976), HB (n = 2358), HA/HB (n = 3), and hemophilia not otherwise specified (n = 4). Variants were detected in most male patients (98.2%% HA, 98.1% HB). 1914 unique variants were found (1482 F8, 431 F9); 744 were novel (610 F8, 134 F9). Inhibitor data were available for 6986 subjects (5583 HA; 1403 HB). In severe HA, genotypes with the highest inhibitor rates were large deletions (77/80), complex intron 22 inversions (9/17), and no variant found (7/14). In severe HB, the highest rates were large deletions (24/42). Inhibitors were reported in 27.3% of Black versus 16.2% of White patients. Conclusions The findings of MLOF are reported, the largest hemophilia genotyping project performed to date. The results support the need for comprehensive genetic approaches in hemophilia. This effort has contributed significantly towards better understanding variation in the F8 and F9 genes in hemophilia and risks of inhibitor formation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据